The sports nutrition industry generates significant revenue on the gap between what ingredient manufacturers claim and what the peer-reviewed literature supports. Protein works. Creatine works. Beyond that, the evidence landscape becomes significantly more complex, and the marketing vocabulary ("proven," "clinically validated," "scientifically backed") is used so consistently that it has lost most of its signal value.
This guide is a clinical evidence review for the ingredients appearing most frequently in next-generation sports nutrition product development. For each, the standard reviewed is the same: what do well-designed human RCTs show, at what dose, and does that dose and format translate to commercially viable products?
The Established Foundation: Why Protein and Creatine Lead
Before addressing the "next generation" ingredients, it is worth being explicit about why protein and creatine remain the foundation.
Protein: The mechanism (muscle protein synthesis via mTOR pathway), the effective dose (0.25–0.40g/kg per meal; 1.6–2.2g/kg/day total), the timing effect (post-training window is real but the overall daily intake is more important), and the quality hierarchy (PDCAAS/DIAAS, branched-chain amino acid content) are among the most consistently replicated findings in sports nutrition science. The formulation implication is straightforward: if you are building a sports nutrition product, protein quality and dose need to be sufficient and clearly communicated before anything else matters.
Creatine monohydrate: The mechanism (phosphocreatine resynthesis; cell volumization effect supporting protein synthesis), the effective dose (3–5g/day for maintenance; loading protocol optional), the format (monohydrate is equivalent or superior to all alternative forms based on current evidence), and the absence of safety signals at standard doses (documented through 30+ years of research) make creatine the clearest add-on to protein in any performance product brief. Forms marketed as superior to monohydrate (creatine HCl, creatine ethyl ester, buffered creatine) do not have evidence of superior performance at equivalent doses.
Next-Generation Ingredients: The Evidence Review
Collagen Peptides (Hydrolyzed Collagen)
Evidence level: Moderate and growing
Collagen peptides have accumulated a meaningful RCT base in two application areas:
Joint and connective tissue health: Several well-designed RCTs (notably a 2017 Penn State study using 15g/day hydrolyzed collagen in athletes over 24 weeks) show significant improvements in joint pain during activity vs. placebo. The proposed mechanism — delivery of glycine, proline, and hydroxyproline dipeptides that upregulate collagen synthesis in connective tissue — is biologically plausible and supported by in vitro data.
Skin integrity: Multiple RCTs showing significant improvements in skin hydration, elasticity, and collagen density with 5–10g/day hydrolyzed collagen. This application is well-established.
The critical formulation nuance: Collagen peptides are not a complete protein source. They have a very poor PDCAAS (~0.08) due to near-absence of tryptophan and low content of several other essential amino acids. Products that market collagen as a primary protein source are misleading consumers about protein quality. The correct positioning is connective tissue and skin support — not a protein claim.
Effective dose: 10–15g/day for joint outcomes; 5–10g/day for skin outcomes. Most commercial products deliver 5–10g/serving. Timing relative to exercise may matter (pre-exercise timing with Vitamin C has mechanistic support for maximizing tendon collagen synthesis) — few products communicate this.
Stability: Collagen peptides are thermally stable and soluble over a wide pH range. Good stability in beverage formats. No significant formulation challenges.
Beta-Alanine
Evidence level: Strong (mechanism and dose well-defined)
Beta-alanine is one of the most evidence-backed ergogenic aids after protein and creatine. The mechanism is direct: beta-alanine increases muscle carnosine content, which buffers lactic acid accumulation during high-intensity exercise, delaying fatigue in activities lasting 1–4 minutes.
Effective dose: 4–6g/day, taken in divided doses of ≤1.6g to reduce paresthesia (the harmless but often uncomfortable tingling sensation that is the primary limiting factor for consumer compliance).
The palatability problem: Beta-alanine paresthesia (tingling of the skin, particularly face and hands) is the most effective reminder that a consumer has taken an active dose — but it is also the reason many consumers discontinue use. Sustained-release formulations reduce paresthesia while maintaining efficacy. Products using beta-alanine without informing consumers about the expected sensory effect generate complaint volume that damage brand trust.
What it does not do: Beta-alanine has no effect on strength output, aerobic endurance, or body composition. The clinical signal is specifically in the 1–4 minute high-intensity effort range. Marketing it as a general performance enhancer is an overreach of the evidence.
Exogenous Ketones (BHB Salts and Ketone Esters)
Evidence level: Moderate (mechanism clear; practical implementation complicated)
Beta-hydroxybutyrate (BHB) is a metabolically active ketone that can serve as a direct substrate for aerobic energy production, providing an alternative fuel source for muscles and the brain during high-intensity exercise.
The mechanism is real: BHB produces ATP in the mitochondria via the same pathway as fatty acid oxidation. In animal models and early human studies, exogenous ketone supplementation raises blood BHB levels and — under specific conditions — spares muscle glycogen during endurance exercise.
The practical complications:
- GI tolerance: BHB salts at effective doses (10–15g) cause significant GI distress in a meaningful proportion of users. This is not a minor side effect — it is the reason adoption of ketone salt products is limited despite the theoretical appeal.
- Salt load: BHB is typically sold as a sodium, calcium, or magnesium salt. Delivering 10–15g of BHB requires proportional mineral delivery that may be undesirable in some contexts.
- Taste: BHB salts are intensely bitter. The flavor challenge at effective doses is significant and limits product format options. Ketone esters (the more effective form) are even worse on taste.
- Cost: Ketone ester products capable of meaningfully elevating blood BHB cost $25–$30 per serving at current pricing. This is a niche premium ingredient, not a mainstream one.
Formulation implication: BHB salts at 5–8g/serving can be incorporated into pre-workout or endurance beverage formulas with careful flavor masking. This dose is below the threshold for strong clinical effects but may provide modest substrate support. At doses needed for meaningful ergogenic effects (10–15g+), the GI and taste challenges are, for most products, commercially prohibitive.
NMN and NR (NAD+ Precursors)
Evidence level: Emerging (strong preclinical; growing but limited RCT base)
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular energy metabolism and DNA repair. NAD+ levels decline with age, and this decline is implicated in the biological mechanisms of aging.
What the current RCTs show:
- NMN at 250–1,200mg/day significantly increases blood NAD+ levels in healthy adults (Yoshino et al., 2021; multiple confirmatory studies)
- NR at 1,000–2,000mg/day similarly raises blood NAD+ levels
- Functional outcomes in healthy middle-aged adults: modest improvements in muscle function and aerobic capacity in a 2021 Washington University NMN RCT; sleep quality improvements in NR studies
- No serious adverse effects at studied doses in published trials
The honest positioning: The NAD+ precursor category has enormous biological plausibility based on the science of aging and cellular energy metabolism. The human RCT base, while growing, is not yet at the level of certainty that justifies the bold longevity and performance marketing language being used. The strongest defensible claim is "supports cellular energy metabolism" — not "reverses aging" or "optimizes athletic performance."
Cost and dose: NMN and NR are expensive ingredients. Effective doses in published trials (500–1,000mg/day) produce a significant COGS impact. These are premium tier ingredients appropriate for premium-priced products where the consumer is seeking evidence-based longevity support.
Lactate (L-Lactic Acid)
Evidence level: Early; scientifically interesting
One of the most counterintuitive developments in sports nutrition science in the past decade is the rehabilitation of lactate as an ergogenic compound. Conventional sports science taught that lactate was a metabolic waste product responsible for muscle fatigue. Contemporary research has established that lactate is an active metabolic substrate — the heart, brain, and slow-twitch muscle fibers preferentially use lactate as a fuel source.
The formulation frontier: Several startups are developing products with exogenous sodium lactate designed to provide oxidizable substrate during high-intensity exercise. The clinical evidence is preliminary — mostly small human studies and preclinical work — but the mechanism is sound and distinct from existing ergogenic categories.
Current status: Too early for primary product claims; appropriate for inclusion in a "recovery" or "metabolic support" product framework as the evidence develops.
The Sports Nutrition Positioning Spectrum
Formulation Principles for Performance Products
Key Takeaways
- Protein and creatine remain the most evidence-backed performance ingredients. Any sports nutrition product should establish the foundation before adding secondary ingredients.
- Collagen peptides are legitimate for joint health and skin — not as a protein source. Communicate the distinction clearly.
- Beta-alanine works specifically for 1–4 minute high-intensity efforts. Disclose paresthesia to consumers; use sustained-release form to improve compliance.
- BHB ketones have mechanism but significant palatability and GI tolerance limitations at effective doses.
- NMN/NR have biological plausibility and growing RCT support — appropriate for premium positioning with modest, accurate claims.
- Dose integrity is the single most common failure in sports nutrition formulation. If an ingredient is present below its effective dose, it cannot be the basis of a claim.
Building a Performance Nutrition Product?
We specialize in sports nutrition formulation that leads with the science — real doses, validated ingredients, and claims built on evidence rather than marketing precedent. If you want to build a product that holds up to both regulatory scrutiny and sophisticated consumer skepticism, let's work together.
"The formulation team knew the clinical literature inside out. We launched with real doses and defensible claims — which has become a genuine differentiator as our category gets more scrutinized."
— Co-Founder, Performance Nutrition Brand